Barclays’s Terns Pharmaceuticals TERN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-669,601
| Closed | -$35.3M | – | 5629 |
|
|
2026
Q1 | $35.3M | Buy |
669,601
+498,415
| +291% | +$20.5M | 0.01% | 858 |
|
|
2025
Q4 | $6.92M | Buy |
171,186
+40,795
| +31% | +$943K | ﹤0.01% | 1971 |
|
|
2025
Q3 | $979K | Sell |
130,391
-114,246
| -47% | -$729K | ﹤0.01% | 3379 |
|
|
2025
Q2 | $912K | Sell |
244,637
-408,400
| -63% | -$1.28M | ﹤0.01% | 3401 |
|
|
2025
Q1 | $1.8M | Sell |
653,037
-51,334
| -7% | -$210K | ﹤0.01% | 2711 |
|
|
2024
Q4 | $3.9M | Buy |
704,371
+609,469
| +642% | +$4.13M | ﹤0.01% | 2379 |
|
|
2024
Q3 | $791K | Sell |
94,902
-100,540
| -51% | -$827K | ﹤0.01% | 3510 |
|
|
2024
Q2 | $1.33M | Sell |
195,442
-52,862
| -21% | -$320K | ﹤0.01% | 2415 |
|
|
2024
Q1 | $1.63M | Buy |
248,304
+163,722
| +194% | +$1.07M | ﹤0.01% | 2740 |
|
|
2023
Q4 | $549K | Buy |
84,582
+30,255
| +56% | +$160K | ﹤0.01% | 3817 |
|
|
2023
Q3 | $273K | Sell |
54,327
-208,591
| -79% | -$1.32M | ﹤0.01% | 3134 |
|
|
2023
Q2 | $2.3M | Sell |
262,918
-271,842
| -51% | -$3.17M | ﹤0.01% | 1801 |
|
|
2023
Q1 | $6.33M | Buy |
534,760
+18,021
| +3% | +$172K | ﹤0.01% | 1405 |
|
|
2022
Q4 | $5.26M | Sell |
516,739
-142,359
| -22% | -$948K | ﹤0.01% | 1584 |
|
|
2022
Q3 | $3.88M | Buy |
659,098
+645,973
| +4,922% | +$2.4M | ﹤0.01% | 1320 |
|
|
2022
Q2 | $33K | Sell |
13,125
-2,227
| -15% | -$4.45K | ﹤0.01% | 4207 |
|
|
2022
Q1 | $46K | Buy |
+15,352
| New | +$65.5K | ﹤0.01% | 4151 |
|
Other funds holding TERN
Barclays's TERN Position: Q2 2026 in Review
Barclays sold out of Terns Pharmaceuticals (TERN) in Q2 2026, closing a stake of 669,601 shares — an estimated $35.3M sold.
Barclays first reported a position in TERN in Q1 2022 and held it in 17 quarters. The position peaked at $35.3M in Q1 2026. 1 fund tracked by Wall St. Rank holds TERN as of Q2 2026.
- Barclays reported no remaining Terns Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- Barclays sold 669,601 Terns Pharmaceuticals shares in Q2 2026, an estimated $35.3M.
- Barclays first reported a position in Terns Pharmaceuticals in Q1 2022 and held it in 17 quarters.
- Barclays's Terns Pharmaceuticals position peaked at $35.3M in Q1 2026.
- 1 fund tracked by Wall St. Rank held Terns Pharmaceuticals as of Q2 2026.
Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.